Title |
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
|
---|---|
Published in |
ClinicoEconomics and Outcomes Research: CEOR, September 2013
|
DOI | 10.2147/ceor.s47486 |
Pubmed ID | |
Authors |
Timothy Juday, Todd Correll, Ayanna Anene, Michael S Broder, Jesse Ortendahl, Tanya Bentley |
Abstract |
February 2013 US treatment guidelines recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir (Atripla®) as a preferred regimen and the once-daily tablet of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild™) as an alternative regimen for first-line treatment of human immunodeficiency virus (HIV). This study assessed the clinical and economic trade-offs involved in using Atripla compared with Stribild as first-line antiretroviral therapy in HIV-infected US adults. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 67% |
Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 14 | 29% |
Student > Master | 11 | 23% |
Other | 5 | 10% |
Student > Postgraduate | 4 | 8% |
Researcher | 4 | 8% |
Other | 5 | 10% |
Unknown | 5 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 25% |
Agricultural and Biological Sciences | 6 | 13% |
Business, Management and Accounting | 4 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
Biochemistry, Genetics and Molecular Biology | 3 | 6% |
Other | 12 | 25% |
Unknown | 7 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2013.
All research outputs
#17,348,622
of 25,457,858 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#331
of 525 outputs
Outputs of similar age
#134,358
of 212,692 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#12
of 16 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,692 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.